Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Genzyme submits applications to FDA and EMA for approval of LEMTRADA™ (alemtuzumab) for multiple sclerosis
Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Fingolimod is a potential novel therapy for multiple sclerosis.
Acid-sensing ion channel 1 is involved in both axonal injury and demyelination in multiple sclerosis and its animal model.
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
New Tysabri data reaffirm substantial efficacy in treatment of people with MS and demonstrate stability of anti-JCV antibody status
Efficacy and Tolerability of BAF312 in Patients With Polymyositis
URMC rheumatologist presents data showing drug’s potential to ease arthritis symptoms
Glatiramer acetate treatment negatively regulates type I interferon signaling.
Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity.
A meta-analysis of whole genome linkage screens in multiple sclerosis.
Background information on multiple sclerosis patients stopping ongoing immunomodulatory therapy: a multicenter study in a community-based environment.
Daclizumab for relapsing remitting multiple sclerosis.
Alemtuzumab improves contrast sensitivity in patients with relapsing-remitting multiple sclerosis.
The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis.
CHMP adopts positive opinion for PLEGRIDY™ (peginterferon beta-1a) as a treatment for multiple sclerosis in the European Union
Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study.
Repurposing the NRF2 activator dimethyl fumarate as therapy against synucleinopathy in Parkinson's disease.
The role of alemtuzumab in facilitating maintenance immunosuppression minimization following solid organ transplantation.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Genzyme’s Lemtrada Recommended for Reimbursement on NHS by the National Institute for Health and Care Excellence (NICE)
Cladribine
FTY720/Fingolimod, a Sphingosine Analogue, Reduces Amyloid-β Production in Neurons.
Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis.

Pages